Body Handbook კატალოგი პროფილი რეიტინგი
ძილი BODY HANDBOOK
ძილი · §199
tirzepatide (Zepbound) ძილის აპნოესთვის
The first drug ever approved for sleep apnea isn't a sleep drug. It's tirzepatide, a weekly weight-loss injection — and because obesity is what crowds the airway shut in most severe cases, taking the weight off treats the apnea too. Over a year, about half of people end up with their sleep tests near normal. The catch: about $12,000 a year, the gains reverse when you stop, and a CPAP mask still works better for anyone who can wear one.
გადაწყვიტე · ყოველკვირა მტკიცებულება ზომიერი თავი ძილი

Adult sleep apnea is mostly an obesity story. Fat builds inside the throat and tongue, so lying down the airway collapses dozens of times an hour. Take the weight off and it opens back up, tracking the tongue fat that goes with it 1. The drug pulls that lever — the fat crowding the airway, not the breathing muscles 2.

The numbers are large. Over a year on the full dose, breathing pauses fell by 25 to 29 events an hour versus almost nothing on placebo; about half ended below the mild-apnea line, blood pressure down 7 to 9 points 3. That earned the first-ever FDA approval for a sleep-apnea drug 4, beating every other apnea drug tested 5.

Untreated, this isn't just tiredness: over two decades, severe apnea roughly doubles the odds of dying, mostly through cardiovascular damage 6. About 15 percent of middle-aged men have it moderate-to-severe, and most have no idea 7.

Treat this as a decision to make with a doctor, one that fits the overweight adult who has failed or refused a mask.

The mask is still the better fix — if you wear it. Worn more than four hours a night, CPAP almost completely normalises breathing 8. But a third to half of people abandon it within a year 9, and the trial on whether it prevents heart attacks came back null on that same problem 10. For the many who can't, tirzepatide beats the fallbacks: mouthpieces, surgery, nerve stimulators.

Price is the real gate. US list runs about $1,000 to $1,350 a month, roughly $12,000 to $16,000 a year without coverage. The sleep-apnea indication changes the math: coded as medical necessity, it's now covered by several large payers and by Medicare for this use, on a prior-authorisation form. Commercial savings cards can drop that toward $25 a month.

What a year on it looks like. Month one is mostly tolerating side effects. By month three the scale has moved 5 to 8 percent; by month six you're into double digits and the bedroom gets quieter. Blood pressure at the next visit is lower. A repeat sleep study around month nine to twelve usually shows the breathing pauses halved or better 3.

The fine print — when to skip it, and what people get wrong

Skip it if: you or a close relative had medullary thyroid cancer or MEN2; you're pregnant, breastfeeding, or conceiving within two months; or you have an active eating disorder. On insulin or a sulfonylurea, the dose must drop or blood sugar crashes.

Two ways it fails: the first three months of nausea (one in twenty quit; slower titration and smaller meals carry most through), and stopping. Off semaglutide, two-thirds of the weight came back in a year 11; the apnea returns with it.

What the noise gets wrong: it's not a sleep drug (the effect runs through weight loss, so it isn't for lean people with apnea), it doesn't replace CPAP for anyone who tolerates a mask, and it has no finish line: it works only while you take it.

References
  1. 1Wang et al. (2020). Effect of Weight Loss on Upper Airway Anatomy and the Apnea-Hypopnea Index: The Importance of Tongue Fat. American Journal of Respiratory and Critical Care Medicine. link
  2. 2Schwartz et al. (2008). Obesity and Obstructive Sleep Apnea: Pathogenic Mechanisms and Therapeutic Approaches. Proceedings of the American Thoracic Society. link
  3. 3Malhotra et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. link
  4. 4FDA (2024). FDA Approves First Medication for Obstructive Sleep Apnea. link
  5. 5Sun et al. (2024). Pharmacological Treatment of Obstructive Sleep Apnea: A Systematic Review and Network Meta-Analysis. Journal of Clinical Sleep Medicine. link
  6. 6Young et al. (2008). Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort. Sleep. link
  7. 7Peppard et al. (2013). Increased Prevalence of Sleep-Disordered Breathing in Adults. American Journal of Epidemiology. link
  8. 8Patil et al. (2019). Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine. link
  9. 9Weaver TE, Grunstein RR (2008). Adherence to Continuous Positive Airway Pressure Therapy: The Challenge to Effective Treatment. Proceedings of the American Thoracic Society. link
  10. 10McEvoy et al. (2016). CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. New England Journal of Medicine. link
  11. 11Wilding et al. (2022). Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension. Diabetes, Obesity and Metabolism. link
დაკავშირებული სახელმძღვანელოში (5)
ეხმარება
  • — This drug treats apnea by treating the weight that drives it — an option for people who won't tolerate a CPAP mask.
დაკავშირებული
  • — Sleep apnea is one more condition these incretin drugs help, on top of heart, kidney, and metabolic gains.
  • — Anyone losing weight on tirzepatide for apnea faces the same muscle-loss risk these drugs carry — train and eat protein.
  • — The same drug approved for sleep apnea is a frontline type 2 diabetes medicine. One injection can work both problems.
  • — Weight-driven airway crowding underlies both full apnea and its milder cousin, upper-airway resistance.
·
199